|
1
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dent R, Trudeau M, Pritchard KI, Hanna WM,
Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P and Narod SA:
Triple-negative breast cancer: Clinical features and patterns of
recurrence. Clin Cancer Res. 13:4429–4434. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kyeong S, Cha YJ, Ahn SG, Suh SH, Son EJ
and Ahn SJ: Subtypes of breast cancer show different spatial
distributions of brain metastases. PLoS One. 12:e01885422017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Guo L, Xie G, Wang R, Yang L, Sun L, Xu M,
Yang W and Chung MC: Local treatment for triple-negative breast
cancer patients undergoing chemotherapy: Breast-conserving surgery
or total mastectomy? BMC Cancer. 21:7172021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang X, Wang SS, Huang H, Cai L, Zhao L,
Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, et al: Effect of
capecitabine maintenance therapy using lower dosage and higher
frequency vs observation on disease-free survival among patients
with early-stage triple-negative breast cancer who had received
standard treatment: The SYSUCC-001 randomized clinical trial. JAMA.
325:50–58. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Burchett JB, Knudsen-Clark AM and Altman
BJ: MYC ran up the clock: The complex interplay between MYC and the
molecular circadian clock in cancer. Int J Mol Sci. 22:77612021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fong KM, Kida Y, Zimmerman PV and Smith
PJ: MYCL genotypes and loss of heterozygosity in non-small-cell
lung cancer. Br J Cancer. 74:1975–1978. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Niu F, Dzikiewicz-Krawczyk A, Koerts J, de
Jong D, Wijenberg L, Fernandez Hernandez M, Slezak-Prochazka I,
Winkle M, Kooistra W, van der Sluis T, et al: MiR-378a-3p is
critical for burkitt lymphoma cell growth. Cancers (Basel).
12:35462020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren L, Zhou T, Wang Y, Wu Y, Xu H, Liu J,
Dong X, Yi F, Guo Q, Wang Z, et al: RNF8 induces β-catenin-mediated
c-Myc expression and promotes colon cancer proliferation. Int J
Biol Sci. 16:2051–2062. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lao-On U, Rojvirat P, Chansongkrow P,
Phannasil P, Siritutsoontorn S, Charoensawan V and Jitrapakdee S:
c-Myc directly targets an over-expression of pyruvate carboxylase
in highly invasive breast cancer. Biochim Biophys Acta Mol Basis
Dis. 1866:1656562020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Duffy MJ, O'Grady S, Tang M and Crown J:
MYC as a target for cancer treatment. Cancer Treat Rev.
94:1021542021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang C, Zhang J, Yin J, Gan Y, Xu S, Gu Y
and Huang W: Alternative approaches to target Myc for cancer
treatment. Signal Transduct Target Ther. 6:1172021. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ciampricotti M, Karakousi T, Richards AL,
Quintanal-Villalonga À, Karatza A, Caeser R, Costa EA, Allaj V,
Manoj P, Spainhower KB, et al: Rlf-Mycl gene fusion drives
tumorigenesis and metastasis in a mouse model of small cell lung
cancer. Cancer Discov. 11:3214–3229. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato F, Fiorentino FP, Alibés A, Perucho
M, Sánchez-Céspedes M, Kohno T and Yokota J: MYCL is a target of a
BET bromodomain inhibitor, JQ1, on growth suppression efficacy in
small cell lung cancer cells. Oncotarget. 7:77378–77388. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu Y, Zhu C, Tang L, Chen Q, Guan N, Xu K
and Guan X: MYC dysfunction modulates stemness and tumorigenesis in
breast cancer. Int J Biol Sci. 17:178–187. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Berger A, Brady NJ, Bareja R, Robinson B,
Conteduca V, Augello MA, Puca L, Ahmed A, Dardenne E, Lu X, et al:
N-Myc-mediated epigenetic reprogramming drives lineage plasticity
in advanced prostate cancer. J Clin Invest. 129:3924–3940. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tjaden B, Baum K, Marquardt V, Simon M,
Trajkovic-Arsic M, Kouril T, Siebers B, Lisec J, Siveke JT, Schulte
JH, et al: N-Myc-induced metabolic rewiring creates novel
therapeutic vulnerabilities in neuroblastoma. Sci Rep. 10:71572020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hassan MS, Cwidak N, Johnson C, Däster S,
Eppenberger-Castori S, Awasthi N, Li J, Schwarz MA and von Holzen
U: Therapeutic potential of the cyclin-dependent kinase inhibitor
flavopiridol on c-Myc overexpressing esophageal cancer. Front
Pharmacol. 12:7463852021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Elbadawy M, Usui T, Yamawaki H and Sasaki
K: Emerging roles of C-Myc in cancer stem cell-related signaling
and resistance to cancer chemotherapy: A potential therapeutic
target against colorectal cancer. Int J Mol Sci. 20:23402019.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Harrison DA: The Jak/STAT pathway. Cold
Spring Harb Perspect Biol. 4:a0112052012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Shea JJ, Schwartz DM, Villarino AV,
Gadina M, McInnes IB and Laurence A: The JAK-STAT pathway: Impact
on human disease and therapeutic intervention. Annu Rev Med.
66:311–328. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang T, Fahrmann JF, Lee H, Li YJ,
Tripathi SC, Yue C, Zhang C, Lifshitz V, Song J, Yuan Y, et al:
JAK/STAT3-regulated fatty acid β-oxidation is critical for breast
cancer stem cell self-renewal and chemoresistance. Cell Metab.
27:136–150.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cascione L, Gasparini P, Lovat F, Carasi
S, Pulvirenti A, Ferro A, Alder H, He G, Vecchione A, Croce CM, et
al: Integrated microRNA and mRNA signatures associated with
survival in triple negative breast cancer. PLoS One. 8:e559102013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
National Research Council (US) Committee
for the Update of the Guide for the Care and Use of Laboratory
Animals, . Guide for the care and use of laboratory animals. 8th
edition. National Academies Press (US); Washington, DC: 2011
|
|
28
|
Chen F, Wang Q, Yu X, Yang N, Wang Y, Zeng
Y, Zheng Z, Zhou F and Zhou Y: MCPIP1-mediated NFIC alternative
splicing inhibits proliferation of triple-negative breast cancer
via cyclin D1-Rb-E2F1 axis. Cell Death Dis. 12:3702021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wu Q, Siddharth S and Sharma D: Triple
negative breast cancer: A mountain yet to be scaled despite the
triumphs. Cancers (Basel). 13:36972021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dameri M, Ferrando L, Cirmena G, Vernieri
C, Pruneri G, Ballestrero A and Zoppoli G: Multi-gene testing
overview with a clinical perspective in metastatic triple-negative
breast cancer. Int J Mol Sci. 22:71542021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wei LM, Li XY, Wang ZM, Wang YK, Yao G,
Fan JH and Wang XS: Identification of hub genes in triple-negative
breast cancer by integrated bioinformatics analysis. Gland Surg.
10:799–806. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Z, Li K, Zheng Z and Liu Y:
Cordycepin inhibits colon cancer proliferation by suppressing MYC
expression. BMC Pharmacol Toxicol. 23:122022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Constantinou C, Papadopoulos S, Karyda E,
Alexopoulos A, Agnanti N, Batistatou A and Harisis H: Expression
and clinical significance of claudin-7, PDL-1, PTEN, c-Kit, c-Met,
c-Myc, ALK, CK5/6, CK17, p53, EGFR, Ki67, p63 in triple-negative
breast cancer-a single centre prospective observational study. In
Vivo. 32:303–311. 2018.PubMed/NCBI
|
|
35
|
Xu X, Zhang L, He X, Zhang P, Sun C, Xu X,
Lu Y and Li F: TGF-β plays a vital role in triple-negative breast
cancer (TNBC) drug-resistance through regulating stemness, EMT and
apoptosis. Biochem Biophys Res Commun. 502:160–165. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kaszak I, Witkowska-Piłaszewicz O,
Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F and Jurka P: Role
of cadherins in cancer-a review. Int J Mol Sci. 21:76242020.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bruner H and Derksen PWB: Loss of
E-cadherin-dependent cell-cell adhesion and the development and
progression of cancer. Cold Spring Harb Perspect Biol.
10:a0293302018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kourtidis A, Lu R, Pence LJ and
Anastasiadis PZ: A central role for cadherin signaling in cancer.
Exp Cell Res. 358:78–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cousin H: Cadherins function during the
collective cell migration of xenopus cranial neural crest cells:
Revisiting the role of E-cadherin. Mech Dev. 148:79–88. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhu Y, Zhang Y, Sui Z, Zhang Y, Liu M and
Tang H: USP14 de-ubiquitinates vimentin and miR-320a modulates
USP14 and vimentin to contribute to malignancy in gastric cancer
cells. Oncotarget. 8:48725–48736. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Song X, Liu Z and Yu Z: EGFR promotes the
development of triple negative breast cancer through JAK/STAT3
signaling. Cancer Manag Res. 12:703–717. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liu L, Nam S, Tian Y, Yang F, Wu J, Wang
Y, Scuto A, Polychronopoulos P, Magiatis P, Skaltsounis L and Jove
R: 6-Bromoindirubin-3′-oxime inhibits JAK/STAT3 signaling and
induces apoptosis of human melanoma cells. Cancer Res.
71:3972–3979. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lv J, Yu W, Zhang Y, Cao X, Han L, Hu H
and Wang C: LNK promotes the growth and metastasis of triple
negative breast cancer via activating JAK/STAT3 and ERK1/2 pathway.
Cancer Cell Int. 20:1242020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fang Y, Zhang S, Yin J, Shen YX, Wang H,
Chen XS and Tang H: LINC01535 promotes proliferation and inhibits
apoptosis in esophageal squamous cell cancer by activating the
JAK/STAT3 pathway. Eur Rev Med Pharmacol Sci. 24:3694–3700.
2020.PubMed/NCBI
|
|
45
|
Wang H and Fu Y: NR1D1 suppressed the
growth of ovarian cancer by abrogating the JAK/STAT3 signaling
pathway. BMC Cancer. 21:8712021. View Article : Google Scholar : PubMed/NCBI
|
